The HIV protease inhibitor Indinavir inhibits cell-cycle progression in vitro in lymphocytes of HIV-infected and uninfected individuals

Blood

Volumn 98, Issue 2, 2001, Pages 383-389

  Chavan, Surendra ^a   Kodoth, Sangeetha ^a   Pahwa, Rajendra ^a   Pahwa, Savita ^a  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CASPASE 3; CASPASE 4; CASPASE 5; CASPASE 8; CASPASE 9; DIDANOSINE; FAS ANTIGEN; INDINAVIR; INTERLEUKIN 1BETA CONVERTING ENZYME; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD3; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE; CELL LYSATE; CELL SURVIVAL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IN VITRO STUDY; LEUKEMIA CELL LINE; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS INHIBITION;

EID: 0035880249     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.2.383     Document Type: Article

References (59)

1. Gazzard B. The picture of future therapy. Int J Clin Pract Suppl. 1999;103:45-48.
2. Clumeck N. Choosing the best initial therapy for HIV-1 infection [editorial; comment]. N Engl J Med. 1999;341:1925-1926.
3. Kiso Y. Protease inhibitors [editorial]. Biopolymers. 1999;51:1.
4. Mitsuyasu R. HIV protease inhibitors: immunological insights. AIDS. 1999;13(suppl 1):S19-S27.
5. + T-cell count on viral load response after 6 months of highly active antiretroviral therapy. Clin Ther. 1999;21:1313-1320.
6. Mezzaroma I, Cariesimo M, Pinter E, et al. Clinical and immunologic response without decrease in virus load in patients with AIDS after 24 months of highly active antiretroviral therapy. Clin Infect Dis. 1999;29:1423-1430.
7. + T cell counts despite virologic failure of protease inhibitor-containing antiretroviral combination therapy. J Infect Dis. 2000;181:1808-1812.
8. Famularo G, De Simone C, Marcellini S. Apoptosis: mechanisms and relation to AIDS. Med Hypotheses. 1997;48:423-429.
9. Cotton MF, Cassella C, Rapaport EL, Tseng PO, Marschner S, Finkel TH. Apoptosis in HIV-1 infection. Behring Inst Mitt. 1996;220-231.
10. Chavan SJ, Tamma SL, Kaplan M, Gersten M, Pahwa SG. Reduction in T cell apoptosis in patients with HIV disease following antiretroviral therapy. Clin Immunol. 1999;93:24-33.
11. Aries SP, Weyrich K, Schaaf B, Hansen F, Dennin RH, Dalhoff K. Early T-cell apoptosis and Fas expression during antiretroviral therapy in individuals infected with human immunodeficiency virus-1. Scand J Immunol. 1998;48:86-91.
12. Phenix BN, Angel JB, Mandy F, et al. Decreased HIV-associated T cell apoptosis by HIV protease inhibitors. AIDS Res Hum Retroviruses. 2000;16:559-567.
13. Gulnik S, Erickson JW, Xie D. HIV protease: enzyme function and drug resistance. Vitam Horm. 2000;58:213-256.
14. Navia MA, McKeever BM. A role for the aspartyl protease from the human immunodeficiency virus type 1 (HIV-1) in the orchestration of virus assembly. Ann N Y Acad Sci. 1990;616:73-85.
15. Stennicke HR, Salvesen GS. Catalytic properties of the caspases. Cell Death Differ. 1999;6:1054-1059.
16. Popov ME, Kashparov IV, Rumsh LD, Popov EM. Mechanism of action of aspartic proteases, III: conformational characteristics of HIV-1 protease inhibitor JG-365. Bioorg Khim. 1999;25:418-422.
17. Sloand EM, Kumar PN, Kim S, Chaudhuri A, Weichold FF, Young NS. Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo. Blood. 1999;94:1021-1027.
18. Sloand EM, Maciejewski J, Kumar P, Kim S, Chaudhuri A, Young N. Protease inhibitors stimulate hematopoiesis and decrease apoptosis and ICE expression in CD34(+) cells. Blood. 2000;96:2735-2739.
19. Weichold FF, Bryant JL, Pati S, Barabitskaya O, Gallo RC, Reitz MS Jr. HIV-1 protease inhibitor ritonavir modulates susceptibility to apoptosis of uninfected T cells. J Hum Virol. 1999;2:261-269.
20. Lu W, Andrieu JM. HIV protease inhibitors restore impaired T-cell proliferative response in vivo and in vitro: a viral-suppression-independent mechanism. Blood. 2000;96:250-258.
21. Andre P, Groettrup M, Klenerman P, et al. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci U S A. 1998;95:13120-13124.
22. Schmidtke G, Holzhutter HG, Bogyo M, et al. How an inhibitor of the HIV-I protease modulates proteasome activity. J Biol Chem. 1999;274:35734-35740.
23. Ikezoe T, Daar ES, Hisatake JI, Taguchi H, Koeffler HP. HIV-1 protease inhibitors decrease proliferation and induce differentiation of human myelocytic leukemia cells. Blood. 2000;96:3553-3559.
24. + T-cell clone (PM1): failure to down-regulate CD4 and to interfere with cell-line-tropic HIV-1. J Virol. 1995;69:3712-3720.
25. McCloskey TW, Chavan S, Lakshmi Tamma SM, Pahwa S. Comparison of seven quantitative assays to assess lymphocyte cell death during HIV infection: measurement of induced apoptosis in anti-Fas-treated Jurkat cells and spontaneous apoptosis in peripheral blood mononuclear cells from children infected with HIV. AIDS Res Hum Retroviruses. 1998;14:1413-1422.
26. Bluming AZ, Lynch MJ, Kavanah M, Khiroya R. Transformation antigens on stimulated lymphocytes. J Immunol. 1975;114:717-721.
27. Rizzardi GP, Pantaleo G. Therapeutic perspectives in HIV-1 infection from recent advances in HIV-1 pathogenesis: it is time to move on. J Biol Regul Homeost Agents. 1999;13:151-157.
28. Bright DC. Antiretroviral therapy for HIV infection: a review of current medications and therapies. J Am Optom Assoc. 1999;70:355-383.
29. + T cell turnover in HIV-infected patients. Proc Natl Acad Sci U S A. 2000;97:13778-13783.
30. Snasel J, Pichova I. The cleavage of host cell proteins by HIV-1 protease. Folia Biol (Praha). 1996;42:227-230.
31. Korant BD, Strack P, Frey MW, Rizzo CJ. A cellular anti-apoptosis protein is cleaved by the HIV-1 protease. Adv Exp Med Biol. 1998;436:27-29.
32. Zhang D, Zhang N, Wick MM, Byrn RA. HIV type 1 protease activation of NF-kappa B within T lymphoid cells. AIDS Res Hum Retroviruses. 1995;11:223-230.
33. Imami N, Antonopoulos C, Hardy GA, Gazzard B, Gotch FM. Assessment of type 1 and type 2 cytokines in HIV type 1-infected individuals: impact of highly active antiretroviral therapy. AIDS Res Hum Retroviruses. 1999;20;15:1499-1508.
34. Stylianou E, Aukrust P, Kvale D, Muller F, Froland SS. IL-10 in HIV infection: increasing serum IL-10 levels with disease progression-down-regulatory effect of potent anti-retroviral therapy. Clin Exp Immunol. 1999;116:115-120.
35. + patients treated with highly active antiretroviral therapy and interleukin 2. J Clin Immunol. 1999;19:317-325.
36. Bisset LR, Rothen M, Joller-Jemelka HI, Dubs RW, Grob PJ, Opravil M. Change in circulating levels of the chemokines macrophage inflammatory proteins 1 alpha and 11 beta, RANTES, monocyte chemotactic protein-1 and interleukin-16 following treatment of severely immunodeficient HIV-infected individuals with indinavir. AIDS. 1997;11:485-491.
37. Kornitzer D, Ciechanover A. Modes of regulation of ubiquitin-mediated protein degradation. J Cell Physiol. 2000;182:1-11.
38. Hershko A. Roles of ubiquitin-mediated proteolysis in cell-cycle control. Curr Opin Cell Biol. 1997;9:788-799.
39. + T cells. Immunology. 1999;96:215-219.
40. Cruikshank WW, Lim K, Theodore AC, et al. IL-16 inhibition of CD3-dependent lymphocyte activation and proliferation. J Immunol. 1996;157:5240-5248.
41. + T cell apoptosis in HIV-infected patients. Clin Exp Immunol. 1999;118:412-416.
42. Hazenberg MD, Stuart JW, Otto SA, et al. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood. 2000;95:249-255.
43. Gougeon ML, Montagnier L. Programmed cell death as a mechanism of CD4 and CD8 T cell deletion in AIDS: molecular control and effect of highly active anti-retroviral therapy. Ann N Y Acad Sci. 1999;887:199-212.
44. Ahsan N, Langhoff E. Immunopathogenesis of human immunodeficiency virus. Semin Nephrol. 1998;18:422-435.
45. Peter ME, Ehret A, Berndt C, Krammer PH. AIDS and the death receptors. Br Med Bull. 1997;53:604-616.
46. Chirmule N, Pahwa S. Envelope glycoproteins of human immunodeficiency virus type 1: profound influences on immune functions. Microbiol Rev. 1996;60:386-406.
47. Shostak LD, Ludlow J, Fisk J, et al. Roles of p53 and caspases in the induction of cell cycle arrest and apoptosis by HIV-1 vpr. Exp Cell Res. 1999;251:156-165.
48. McCloskey TW, Ott M, Tribble E, et al. Dual role of HIV Tat in regulation of apoptosis in T cells. J Immunol. 1997;158:1014-1019.
49. Zauli G, Gibellini D, Secchiero P, et al. Human immunodeficiency virus type 1 Nef protein sensitizes CD4(+) T lymphoid cells to apoptosis via functional upregulation of the CD95/CD95 ligand pathway. Blood. 1999;93:1000-1010.
50. Korant BD, Strack P, Frey MW, Rizzo CJ. A cellular anti-apoptosis protein is cleaved by the HIV-1 protease. Adv Exp Med Biol. 1998;436:27-29.
51. Renno T, Attinger A, Locatelli S, Bakker T, Vacheron S, MacDonald HR. Cutting edge: apoptosis of superantigen-activated T cells occurs preferentially after a discrete number of cell divisions in vivo. J Immunol. 1999;162:6312-6315.
52. Halloran PF. Molecular mechanisms of new immunosuppressants. Clin Transplant. 1996;10:118-123.
53. Wentworth JM, Burris TP, Chatterjee VK. HIV protease inhibitors block human preadipocyte differentiation, but not via the PPARgamma/RXR heterodimer. J Endocrinol. 2000;164:R7-R10.
54. Berthold HK, Parhofer KG, Ritter MM, et al. Influence of protease inhibitor therapy on lipoprotein metabolism. J Intern Med. 1999;246:567-575.
55. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection [editorial]. AIDS. 1999;13:2493-2505.
56. Mathe G. Human obesity and thinness, hyperlipidemia, hyperglycemia, and insulin resistance associated with HIV1 protease inhibitors: prevention by alternating several antiproteases in short sequences [editorial]. Biomed Pharmacother. 1999;53:449-451.
57. Gummuluru S, Emerman M. Cell cycle- and Vpr-mediated regulation of human immunodeficiency virus type 1 expression in primary and transformed T-cell lines. J Virol. 1999;73:5422-5430.
58. Domadula G, Zhang H, Shetty S, Pomerantz RJ. HIV-1 virions produced from replicating peripheral blood lymphocytes are more infectious than those from nonproliferating macrophages due to higher levels of intravirion reverse transcripts: implications for pathogenesis and transmission. Virology. 1999;253:10-16.
59. Goh WC, Rogel ME, Kinsey CM, et al, HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo. Nat Med. 1998;4:65-71.